Brazil vs Tunisia: Average cost of multi drug-resistant tuberculosis treatment
Brazil
4,102 constant 2022 US$
in 2024
Tunisia
4,560 constant 2022 US$
in 2023
Brazil rank
10th
Tunisia rank
9th
Average cost of multi drug-resistant tuberculosis treatment over time
- Brazil
- Tunisia
How they compare
Tunisia currently reports 4,560 constant 2022 US$ against 4,102 constant 2022 US$ in Brazil, a difference of 458 constant 2022 US$.
That makes Tunisia's figure about 1.1 times Brazil's.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Tunisia ahead.
Brazil ranks 10th and Tunisia ranks 9th of 92 countries.
Across the 2 decades both report, Brazil averaged higher in 1 and Tunisia in 1.
Head to head by decade
| Decade | Brazil | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,083 constant 2022 US$ | 4,150 constant 2022 US$ | 1,067 constant 2022 US$ | Tunisia |
| 2020s | 3,988 constant 2022 US$ | 3,665 constant 2022 US$ | 323 constant 2022 US$ | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Brazil or Tunisia?
- Tunisia, at 4,560 constant 2022 US$ against 4,102 constant 2022 US$ in Brazil as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Brazil and Tunisia?
- 458 constant 2022 US$, with Tunisia ahead.
- How many years of comparable data are there for Brazil and Tunisia?
- 6 years are reported by both, from 2017 to 2023.
- How do Brazil and Tunisia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Brazil ranks 10th and Tunisia ranks 9th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.